Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
Date:7/30/2010

VANCOUVER, July 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the second quarter ended June 30, 2010.

"We are pleased to report continued quarter over quarter growth in product sales, driven primarily by our most innovative Proprietary Medical Products," said Dr. William Hunter, President and CEO of Angiotech. "In addition, we are encouraged by sales trends for our Base Medical Products, which continued to show steady improvement across all key product groups through the first half of 2010."

Second Quarter Financial Highlights

    -  Total revenue was $61.9 million.

    -  Net product sales were $53.0 million. Sales of our Proprietary Medical
       Products were $16.4 million, or 31% of total product sales. Sales of
       our Base Medical Products were $36.6 million, or 69% of total product
       sales.

    -  Royalty revenue was $8.9 million.

    -  Research and development expenses were $6.9 million.

    -  Selling, general and administrative expenses were $22.8 million.

    -  Net loss and net loss per share were $14.1 million and $0.17,
       respectively.

    -  As of June 30, 2010, cash and short-term investments were
       $35.1 million and net debt was $539.9 million.

Selected Non-GAAP Financial Measures

    -  Certain financial measures in this press release are prepared in
       accordance with United States Generally Accepted Accounting Principles
       ("GAAP"). In addition, certain financial measures presented below and
       in the appendix to this press release are non-GAAP, or adjusted,
       financial measures that exclude certain items. Management uses certain
       non-GAAP, or adjusted, finan
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
2. Angiotech Pharmaceuticals Announces Conference Call and Webcast
3. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
4. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
5. Angiotech Pharmaceuticals Announces Conference Call and Webcast
6. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
7. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
8. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
9. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
10. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... --  GenoSpace , a precision medicine software company that ... the broad use of genomic data in research and ... Phase I of a Fast Track Small Business Innovation ... (NIH) to enable enhanced data access and cohort construction ... During the past decade, the cost ...
(Date:9/23/2014)... SC (PRWEB) September 23, 2014 Dr. ... my third book on healthcare offers a three phase ... 21st century healthcare delivery system that would go far ... state’s responsibility regarding the delivery of healthcare.” , “Every ... safety has failed to provide discernable progress throughout that ...
(Date:9/22/2014)... treated with a statin in the hospital after suffering ... survive than those who were not, according to a ... study was conducted by the same researchers who recently ... survival in victims of ischemic stroke., Ischemic stroke is ... vessel that blocks blood from reaching areas of the ...
(Date:9/22/2014)... by researchers at the USC Viterbi School of ... 3-D microfluidic system quickly and cheaply by simply ... Microfluidic systems are used in many fields including ... volumes of fluids for use in applications such ... diagnostic testing, and synthetic chemistry. Traditionally, microfluidic devices ...
Breaking Biology Technology:GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5
... men of action. Lies do not become us." , ,- ... business owners sometime seem like a big challenge to marketers. ... the right opportunity, however, small business owners can also be ... a desirable and growing market to many businesses. According to ...
... exodus continues at Merge Technologies, Inc. , ,The ... Healthcare, has announced that it received "a written notification from ... and president of Merge subsidiary Cedara Software , of ... 18. , ,Pedlar is the fifth executive to leave the ...
... - GE Healthcare will have the exclusive ... the terms of a 15-year agreement with its developer, ... will supply the stem cell harvesting product, known as the ... one of the world's largest chains of private umbilical cord ...
Cached Biology Technology:Big opportunities with small businesses 2Big opportunities with small businesses 3Pedlar the latest executive to leave Merge 2
(Date:9/23/2014)... today that the Company has secured $21 million in ... used to expand the Company,s cancer immunotherapy pipeline and ... Yuan Capital led the round, with participation from Majuven ... Suma Venture and Harbinger Venture Capital. , Eureka ... antibodies engineered to mimic the functions of a T ...
(Date:9/23/2014)... turn it is to do the washing up, negotiating rights ... as many students returning to university for the new academic ... house can be a tricky business. , And now research ... new technology to allow people to monitor their energy usage ... tension. , The study by a team of technology experts ...
(Date:9/23/2014)... could be as good for your mental as your ... by the University of Warwick,s Medical School using data ... BMJ Open focused on mental wellbeing and ... associated with an individual,s fruit and vegetable consumption. , ... or more portions of fruit and vegetables a day, ...
Breaking Biology News(10 mins):Smart meters could cause conflict for housemates, study shows 2Smart meters could cause conflict for housemates, study shows 3Eating five a day may keep the blues away 2
... specialized sensory organ that the malaria mosquito uses to ... of researchers has taken an important step toward developing ... used to reduce the threat of malaria, generally considered ... sensory organ is the maxillary palp. It is one ...
... at St. Jude Childrens Research Hospital provide strong evidence ... which has revolutionized the treatment of chronic myelogenous leukemia, ... particularly aggressive form of acute lymphoblastic leukemia (ALL). Targeted ... a specific molecule, a strategy aimed at making treatments ...
... may be attracted to more than the bananas that are ... carbonated water. Fruit flies detect and are attracted to the ... found on rotting fruits containing yeast, concludes a study appearing ... at the University of California, Berkeley, who conducted the study, ...
Cached Biology News:Advance in effort to fight malaria by tricking the mosquito's sense of smell 2Advance in effort to fight malaria by tricking the mosquito's sense of smell 3St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia 2Researchers find new taste in fruit flies: carbonated water 2Researchers find new taste in fruit flies: carbonated water 3
...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to Nebraska Calf Diarrhea Virus (FITC) ( Abpromise for all tested applications). Antigen: Bovine (Nebraska Calf Diarrhea Virus)....
Biology Products: